Vai al contenuto principale
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Fase 2325 partecipanti ricercati75 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Patologie

  • Major Depressive Disorder

Idoneità

Idoneità
SessoTutti
Età18 Years – 70 Years
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 2
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento325 partecipanti ricercati

Sponsor e collaboratori

  • Alto Neuroscience Sponsor

Bracci e interventi

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

Interventi

  • Farmaco ALTO-300

    ALTO-300 capsule QD

  • Farmaco Placebo

    Placebo capsule QD

Esiti misurati

  1. Esito primario

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Orizzonte temporale Change over time for up to week 6

  2. Esito secondario

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Orizzonte temporale Change over time for up to week 6

  3. Esito secondario

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Orizzonte temporale Change over time for up to week 6

  4. Esito secondario

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    Orizzonte temporale Assessed from Day 1 to Week 14

  5. Esito secondario

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    Orizzonte temporale Assessed from Day 1 to Week 14

  6. Esito secondario

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    Orizzonte temporale Assessed from Day 1 to Week 14

  7. Esito secondario

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    Orizzonte temporale Assessed from Day 1 to Week 14

  8. Esito secondario

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    Orizzonte temporale Assessed from Day 1 to Week 15

Date

Date
Data di inizio8 giugno 2023 (effettiva)
Conclusione primaria1 dicembre 2026 (stimata)
Conclusione1 dicembre 2026 (stimata)
Prima pubblicazione28 giugno 2023 (effettiva)
Ultimo aggiornamento26 ottobre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaottobre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

30 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Site 114AlbuquerqueNew MexicoIn reclutamento
Site 216AllentownPennsylvaniaInterrotto
Site 316AustinTexasIn reclutamento
Site 218BellflowerCaliforniaIn reclutamento
Site 317BlackfootIdahoRitirato
Site 236BoiseIdahoIn reclutamento
Site 119BoiseIdahoAttivo, non in reclutamento
Site 318CarlsbadCaliforniaAttivo, non in reclutamento
Site 310ChicagoIllinoisAttivo, non in reclutamento
Site 202CincinnatiOhioIn reclutamento
Site 159ClermontFloridaInterrotto
Site 207ClintonUtahAttivo, non in reclutamento
Site 203Colorado SpringsColoradoAttivo, non in reclutamento
Site 239ConroeTexasIn reclutamento
Site 229Creve CouerMissouriRitirato
Site 102DallasTexasAttivo, non in reclutamento
Site 343DenverColoradoIn reclutamento
Site 349EvergreenColoradoAttivo, non in reclutamento
Site 345EvergreenColoradoAttivo, non in reclutamento
Site 277FairfaxVirginiaIn reclutamento
Site 238FayettevilleGeorgiaIn reclutamento
Site 148Fort WorthTexasRitirato
Site 347Fort WorthTexasInterrotto
Site 217GlendaleCaliforniaAttivo, non in reclutamento
Site 279HattiesburgMississippiRitirato
Site 199HickoryNorth CarolinaAttivo, non in reclutamento
Site 320HoustonTexasIn reclutamento
Site 275HoustonTexasIn reclutamento
Site 215JacksonMississippiAttivo, non in reclutamento
Site 335LafayetteCaliforniaIn reclutamento
Site 335LafayetteCaliforniaIn reclutamento
Site 344Las VegasNevadaIn reclutamento
Site 209Los AngelesCaliforniaAttivo, non in reclutamento
Site 240MankatoMinnesotaIn reclutamento
Site 201MarreroLouisianaInterrotto
Site 219MatherCaliforniaIn reclutamento
Site 350MediaPennsylvaniaRitirato
Site 225Miami GardensFloridaAttivo, non in reclutamento
Site 190Miami LakesFloridaAttivo, non in reclutamento
Site 265MinneapolisMinnesotaIn reclutamento
Site 194Mission ViejoCaliforniaInterrotto
Site 206Missouri CityTexasRitirato
Site 198MonroeLouisianaInterrotto
Site 267MoorparkCaliforniaIn reclutamento
Site 352MoosicPennsylvaniaAttivo, non in reclutamento
Site 283New YorkNew YorkIn reclutamento
Site 319New YorkNew YorkAttivo, non in reclutamento
Site 214NorwalkConnecticutRitirato
Site 161OkeechobeeFloridaAttivo, non in reclutamento
Site 195Oklahoma CityOklahomaInterrotto

Nella scheda del registro sono indicati altri 25 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 26 ottobre 2026

    Obiettivo di arruolamento modificato

    Enrollment target revised up from 321 to 325

    321325

  2. 26 ottobre 2026

    Centro aggiunto

    30 sites added (75 total)

    4575